SMALL CELL LUNG CARCINOMA (SCLC)
Clinical trials for SMALL CELL LUNG CARCINOMA (SCLC) explained in plain language.
Never miss a new study
Get alerted when new SMALL CELL LUNG CARCINOMA (SCLC) trials appear
Sign up with your email to follow new studies for SMALL CELL LUNG CARCINOMA (SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Scientists test Dual-Attack on Tough-to-Treat lung cancers
Disease control OngoingThis early-stage study is testing a new combination of two immunotherapy drugs, obrixtamig and ezabenlimab, for adults with advanced small cell lung cancer or similar neuroendocrine tumors that have stopped responding to standard treatments. The main goal is to find the highest d…
Matched conditions: SMALL CELL LUNG CARCINOMA (SCLC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New weapon against tough lung cancer enters human testing
Disease control OngoingThis early-stage study aims to find a safe dose of an experimental drug called BI 764532 when given with standard chemotherapy. It is for adults whose extensive-stage small cell lung cancer has worsened after initial platinum-based treatment. The drug is designed to help the body…
Matched conditions: SMALL CELL LUNG CARCINOMA (SCLC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New weapon against aggressive lung cancer enters human testing
Disease control OngoingThis early-stage study is testing a new drug called BI 764532 (obrixtamig) when combined with standard chemotherapy and immunotherapy for extensive-stage small cell lung cancer. The main goal is to find the highest dose patients can safely tolerate. Researchers will also check if…
Matched conditions: SMALL CELL LUNG CARCINOMA (SCLC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC